Natco Pharma Limited has informed the Exchange regarding a press release dated October 19, 2026, titled "NATCO announces launch of Carboplatin Injection (generic of Paraplatin®) in the U.S. market".

Summary by 6ix AI

NATCO Pharma Limited has announced the launch of Carboplatin Injection, a generic version of Paraplatin, in the U.S. market through its subsidiary, NATCO Pharma USA LLC. This launch is in collaboration with Teyro Labs Pvt Ltd and aims to address a critical shortage of the product in the U.S. Carboplatin Injection is indicated for treating advanced ovarian carcinoma and had estimated sales in the U.S. market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries